August 06, 2025

Bimekizumab Sustains Psoriasis Response for 3 Years

A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.

Conexiant

August 05, 2025

Nature’s Mouthwash: Better Breath, Fewer Risks?

Researchers report significant improvements in breath odor and oral health after four weeks using a natural essential oil rinse in patients with obesity and periodontitis.

Conexiant

August 04, 2025

Beta-HPV–Driven SCC Resolved After TCR Signaling Correction

Case study shows cutaneous squamous cell carcinoma linked to beta-human papillomavirus cleared following T-cell immune restoration.

Conexiant

July 31, 2025

Guselkumab Improves Scalp Psoriasis in Patients With Skin of Color

This clinical trial summary highlights the efficacy, safety, and sustained scalp clearance achieved with guselkumab for moderate to severe scalp psoriasis in patients with skin of color.

Conexiant

July 29, 2025

Nonblistering Papules: Genetic Mystery Cracked

A woman with a decades-long history of intensely pruritic, nonblistering papules on her extremities was diagnosed with dystrophic epidermolysis bullosa pruriginosa, confirmed by COL7A1 gene sequencing, after a comprehensive clinicopathologic evaluation.

Conexiant

July 24, 2025

Can a Daily Moisturizer Prevent Eczema?

New trial finds a 16% relative risk reduction in atopic dermatitis with full-body emollient use starting in early infancy—especially effective in low-risk infants and dog-owning households.

Conexiant

July 23, 2025

FDA Grants Breakthrough Status to Melanoma Test

The FDA has granted Breakthrough Device designation to Castle Biosciences’ DecisionDx-Melanoma test, a gene expression profile assay designed to improve risk stratification and personalized care in cutaneous melanoma.

Conexiant

July 14, 2025

Self-Injection Device Effective for Acne Lesions

A new multicenter trial found that self-injected low-dose triamcinolone using an assistance device was as effective and safe as physician-administered injections for inflammatory acne, with improved outcomes at higher doses for severe lesions.

Conexiant

July 21, 2025

Melanoma Risk Differs by Mole Count and Genetic Profile

A large study found distinct genetic and phenotypic risk patterns for nevus-associated and de novo invasive melanomas.

Conexiant